Abstract: Kidney transplantation is an effective treatment for end-stage renal disease. Patients need to take immunosuppressants for a long time to reduce the risk of rejection after transplantation. Although tacrolimus is the most widely used calmodulin immunosuppressant, it exhibits narrow therapeutic window and large individual differences in pharmacokinetics. Among the relevant factors affecting their individual differences, gene polymorphism is one of the hot spots in the recent researches. Through the literature retrieval, the article reviews the effects of familiar gene polymorphisms on the pharmacokinetics of tacrolimus, which aims to elucidate the influence of specific genes on the pharmacokinetics of tacrolimus and provide a reference for improving the level of individualized treatment of tacrolimus.